AstraZeneca’s Tagrisso Combo Extends Survival in Hard-to-Treat Lung Cancer

AstraZeneca has reported a win in one of lung cancer’s tougher settings: patients whose EGFR-mutated tumours have stopped responding to its flagship drug.

In the Phase 3 SAFFRON trial, combining Tagrisso (osimertinib) with Hutchmed’s Orpathys (savolitinib) delayed disease progression or death and extended overall survival compared with chemotherapy.

The resistance problem

EGFR-mutated lung cancer is one of oncology’s success stories. Tumours driven by mutations in the EGFR gene respond well to drugs blocking it, and patients who would once have received chemotherapy alone can achieve long periods of disease control on a daily tablet.

Those responses end. Cancers under sustained selective pressure evolve around the block, and after a period measured in months to a few years the disease progresses again.

Historically the answer at that point was chemotherapy — effective to a degree, considerably harder to tolerate, and a step backwards from targeted treatment.

Why MET is the escape route

Resistance to EGFR inhibitors takes several forms, and one of the most common is amplification of a second driver called MET.

The logic is straightforward from the cancer’s perspective. EGFR and MET feed into overlapping downstream growth pathways, so a tumour that dramatically increases MET signalling can keep those pathways active even while EGFR is blocked. It does not need to mutate EGFR itself; it routes around it.

That makes MET amplification an identifiable, targetable form of resistance rather than a general failure — which is what allows a specific combination to address it.

What the combination does

Adding a MET inhibitor to the EGFR inhibitor shuts down both pathways at once — an all-oral, biomarker-directed approach avoiding chemotherapy.

The combination was tested in EGFR-positive non-small cell lung cancer with a MET alteration, in patients whose disease had worsened after first- or second-line Tagrisso.

The population definition is doing important work. This is not a combination for everyone who progresses on Tagrisso — it is for the subset whose resistance runs through MET, identified by testing. Patients resisting through other mechanisms would gain nothing, and including them would have diluted the effect.

Why extending overall survival matters here

Delaying progression is a common finding in this setting; extending overall survival against chemotherapy is a stronger claim.

Progression-free survival can improve without patients living longer, particularly when the comparator is available afterwards — a patient progressing on the combination can still receive chemotherapy, so the sequence rather than the individual treatment may determine total survival.

Showing an overall survival benefit means the combination did more than reorder the treatment sequence.

Avoiding chemotherapy is a real benefit

The all-oral framing is not marketing. Chemotherapy in advanced lung cancer means infusion visits, hair loss, nausea, neuropathy, blood count suppression and infection risk, in patients who are frequently already symptomatic from their disease.

An oral combination continuing the treatment approach patients were already tolerating, with a side effect profile in a different category, is a substantially different experience — and for a population whose remaining time is measured in months to years, quality of that time is not a secondary consideration.

The commercial and access picture

Tagrisso is approved in major markets; Orpathys is approved in China and Switzerland, with AstraZeneca handling commercialisation.

That asymmetry is the practical constraint. A combination requires both components available, and savolitinib’s limited approvals mean the regimen cannot currently be delivered in most of the world regardless of the SAFFRON result.

“We aim to deliver the first biomarker-directed, all-oral option in this setting to patients across the globe,” said Susan Galbraith, AstraZeneca’s oncology R&D chief — which is a statement about filings to come.

The testing requirement

A biomarker-directed regimen only reaches patients who are tested. Identifying MET alteration at progression requires re-biopsy or circulating tumour DNA testing, and repeat molecular profiling at progression is not universal practice.

Why repeat molecular testing is the bottleneck

A biomarker-directed regimen for resistance depends on a step that frequently does not happen: testing the tumour again after it progresses.

Molecular profiling at diagnosis is now standard in lung cancer, because it determines first-line treatment. Repeating it at progression is not, and the reasons are practical. Re-biopsy of a lung lesion is invasive and carries risk in patients who are frequently unwell; circulating tumour DNA testing avoids that but is less sensitive and not universally reimbursed.

There is also a workflow problem. A patient progressing on treatment needs a decision quickly, and waiting weeks for molecular results while the disease advances is a genuine clinical dilemma — which pushes clinicians toward starting chemotherapy rather than waiting to see whether a targeted option exists.

So a combination proven effective in MET-altered disease will reach patients in proportion to how routinely resistance is characterised. The drug result and the testing pathway are equally determinative, and only one of them is addressed by a trial.

The result strengthens the case for treating resistance with a precision combination rather than falling back on chemotherapy — and realising that depends as much on testing pathways as on the drugs. Clinical and business news, not medical advice.